Introduction {#Sec1}
============

Patients with profound and prolonged neutropenia are at a major risk of infection \[[@CR1]\]. Febrile neutropenia is generally a complication of myelosuppressive chemotherapy and requires immediate evaluation to avoid progression to a sepsis syndrome and possibly death \[[@CR2], [@CR3]\].

Gram-positive bacteria are currently the leading agents responsible for infections in patients with neutropenia worldwide \[[@CR4]\]. Moreover, a major concern is that resistant Gram-positive pathogens, such as methicillin-resistant *Staphylococcus aureus* (MRSA) and vancomycin-resistant enterococci (VRE), have become common in these patients. Thus, in some centers, MRSA and VRE are the most prevalent resistant isolates, accounting for up to 20% and 50% of episodes, respectively \[[@CR5]\].

In patients with fever and neutropenia, recent guidelines do not recommend empiric therapy with antimicrobials, such as vancomycin, linezolid or daptomycin, but suggest early administration of these agents for patients with specific clinical indications or who are at risk of exposure to resistant bacteria \[[@CR5]\]. These situations include patients with hemodynamic instability, suspected catheter-related infection, skin or soft tissue infection, pneumonia, previous infection or colonization with MRSA or VRE, or a hospital setting with high rates of resistant Gram-positive pathogens \[[@CR5]\].

Vancomycin has been the mainstay of therapy for infections caused by resistant Gram-positive pathogens, such as MRSA, for several decades \[[@CR6]\]. However, in patients with febrile neutropenia, it is associated with a delayed response and the development of resistant organisms \[[@CR7]\]. Moreover, recent guidelines recommend using alternatives when the vancomycin minimum inhibitory concentration (MIC) of the infecting MRSA strain is increased \[[@CR8], [@CR9]\]. Indeed, many reports suggest a link between a higher vancomycin MIC of the infecting pathogen and a worse clinical outcome in patients with an MRSA infection \[[@CR10]\].

To improve the outcome of these vulnerable patients with neutropenia, daptomycin is an attractive agent because of its broad spectrum of activity and its bactericidal action. It is a lipopeptide antibiotic with rapid bactericidal activity against most clinically relevant Gram-positive pathogens, including many antibiotic-resistant strains \[[@CR11]--[@CR13]\]. Daptomycin has not been formally evaluated in randomized trials in patients with neutropenia, but several case reports and abstracts have been published documenting its potential in this setting \[[@CR14]--[@CR16]\]. The retrospective analysis from the Cubicin^®^ Outcome Registry and Experience (CORE) showed that daptomycin was effective and well tolerated in patients with neutropenia \[[@CR17]\].

The European CORE (EU-CORE^SM^) was designed to collect real-world demographic and clinical data on patients treated with daptomycin. The goal of the present analysis was to describe the clinical outcome and safety of daptomycin in patients with neutropenia treated for documented Gram-positive infections.

Methods {#Sec2}
=======

Study Design and Data Collection {#Sec3}
--------------------------------

EU-CORE was a non-interventional, multicenter, retrospective, patient registry designed to collect real-world outcome in patients treated with daptomycin for Gram-positive infections. Detailed EU-CORE methodology has been described elsewhere \[[@CR18]\]. Briefly, local investigators from 18 countries in Europe (12), Latin America (5), and Asia (1) collected demographic, primary infection, prior and concomitant antibiotics, clinical, and microbiologic data using standardized case-report forms for patients with Gram-positive infections who had received at least one dose of daptomycin between January 2006 and April 2012, and had had at least 30 days of post-treatment follow-up. Patients who had received daptomycin as part of a controlled clinical trial were excluded.

For the present analysis, patients with an absolute neutrophil count (ANC) ≤1000 cells/mm^3^ at baseline or during daptomycin treatment were selected. Patients were stratified into three categories based on the ANC: those with severe (≤100 cells/mm^3^), moderate (101--499 cells/mm^3^), and mild (500--1000 cells/mm^3^) neutropenia \[[@CR5], [@CR19]\].

Institutional review board (IRB) approval was obtained before the start of the study and all procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013, and Good Clinical Practices. Informed consent was obtained according to the requirements of the IRB and/or local data privacy regulations.

Clinical Outcomes and Safety {#Sec4}
----------------------------

Local investigators assessed clinical outcomes at the end of daptomycin therapy according to protocol-defined criteria: (1) cured, clinical signs and symptoms resolved, no additional antibiotic therapy was necessary, or infection cleared with a negative culture reported; (2) improved, partial resolution of clinical signs and symptoms and/or additional antibiotic therapy was warranted; (3) failed, inadequate response to daptomycin therapy, worsening or new/recurrent signs and symptoms, need for a change in antibiotic therapy, or positive culture reported at the end of the therapy; and (4) non-evaluable, unable to determine response because of insufficient information \[[@CR20]\]. Clinical success was used to describe collectively patients with an outcome of cured or improved. Time to improvement was also recorded. Duration of treatment was measured as the number of inpatient and outpatient days during which the patient received daptomycin therapy, even if these were non-consecutive.

Adverse events (AEs) and serious AEs (SAEs) during daptomycin treatment, and 30-day follow-up period were assessed by the investigators. All deaths, AEs, and SAEs were recorded, regardless of their relation to daptomycin.

Statistical Analysis {#Sec5}
--------------------

The safety population included all eligible patients with at least one safety assessment and the efficacy population included all eligible patients for whom clinical outcome was assessed.

Given that this was a registry, no inferential analyses were conducted and no formal statistical methodology other than simple descriptive statistics was used. All analyses were considered to be explanatory. Continuous variables were summarized as arithmetic mean, standard deviation, median, and range; categorical variables were summarized by absolute and relative frequencies.

Statistical analysis was performed using SAS version 9.3 (SAS Institute Inc., Cary, NC, USA).

Results {#Sec6}
=======

Patient Demographic and Clinical Characteristics {#Sec7}
------------------------------------------------

Of the 6075 patients enrolled in EU-CORE registry who had received at least one dose of daptomycin, 446 (7.3%) had an ANC ≤1000 cells/mm^3^ at baseline or during daptomycin treatment; 50% (*n* = 223) had severe neutropenia (ANC ≤100 cells/mm^3^). All patients selected for the present analysis were included in both safety and efficacy populations. Baseline demographics and clinical characteristics of patients are summarized in Table [1](#Tab1){ref-type="table"}. Overall, 58.5% (*n* = 261) of patients were men and 26.2% (*n* = 117) had an age ≥65 years. The most common underlying diseases were hematologic malignancy (60.5%; *n* = 270), immunosuppressed state (39.7%; *n* = 177), and transplant (27.8%; *n* = 124).Table 1Demographic and clinical characteristicsCharacteristics*N* = 446*n* (%)Male gender261 (58.5)Age, years Median (range)54.5 (4--94) \<65329 (73.8) ≥65 (including ≥75)117 (26.2) ≥7532 (7.2)Race^a^, Caucasian393 (88.1)Body weight (kg), median (range)71.0 (18--138)Renal impairment at initiation of daptomycin 30 \< CrCl \< 50 mL/min42 (9.4) CrCl \<30 mL/min25 (5.6) Dialysis14 (3.1)Underlying diseases^b^ (\>5% of patients) Hematologic malignancy270 (60.5) Immunosuppressed state177 (39.7) Transplant124 (27.8) Anemia and/or all hematological diseases90 (20.2) Hypertension44 (9.9) Cancer (solid organ)39 (8.7) Diabetes mellitus36 (8.1) Sepsis26 (5.8)Antibiotic therapy before initiation of daptomycin319 (71.5) Penicillins167 (37.4) Glycopeptides145 (32.5) Carbapenems98 (22.0)Absolute neutrophil count (cells/mm^3^)^c^ ≤100223 (50.0) 101--49977 (17.3) 500--1000131 (29.4) Missing data15 (3.4)Results are given as *n* (%) unless otherwise indicated*CrCl* creatinine clearance^a^Missing data for *n* = 19^b^More than one underlying disease could be reported^c^Lowest count at baseline or during daptomycin treatment

The most common primary infections were catheter-related bacteremia (30.5%; *n* = 136), non-catheter-related bacteremia (11.7%; *n* = 52), and complicated skin and soft tissue infection (cSSTI; 13.9%; *n* = 62) (Table [2](#Tab2){ref-type="table"}).Table 2Type of primary infectionInfection type^a^*N* = 446*n* (%)Bacteremia188 (42.2)Catheter related136 (30.5)Non-catheter related52 (11.7)Complicated skin and soft tissue infection62 (13.9)Uncomplicated skin and soft tissue infections26 (5.8)Foreign body and/or prosthetic infection20 (4.5)Neutropenic fever19 (4.3)Endocarditis15 (3.4)Osteomyelitis, non-prosthetic and prosthetic device related11 (2.5)Other^b^105 (23.5)^a^A patient could have different infection types^b^Includes surgical/non-surgical antibiotic prophylaxis, urinary tract infection/pyelonephritis, necrotizing infections, metastatic abscess, septic arthritis, central nervous system infection, and otherwise unspecified infections

Microbiology {#Sec8}
------------

Results of cultures were available for 83.0% (*n* = 370) of patients and were positive for 68.6% (*n* = 254) of them (Table [3](#Tab3){ref-type="table"}). The most common pathogens were coagulase-negative staphylococci (CoNS), which were identified in 43.7% (*n* = 111) of patients with positive culture and *S. aureus* in 18.9% (*n* = 48), with MRSA in 9.1% (*n* = 23). VRE were reported in 5.5% (*n* = 14) of patients.Table 3Microbiologic data in patients with neutropenia with positive culturesPrimary pathogens*N* = 254*n* (%)Coagulase-negative staphylococci (CoNS)111 (43.7) *Staphylococcus epidermidis*64 (25.2) Other47 (18.5)*Staphylococcus aureus*48 (18.9) Methicillin resistant (MRSA)23 (9.1) Methicillin susceptible (MSSA)20 (7.9) Methicillin susceptibility unknown5 (2.0)Enterococci (*E. faecalis*, *E. faecium* or other species)35 (13.8) *Enterococcus faecium*23 (9.1) *Enterococcus faecalis*9 (3.5) Vancomycin resistant (*E. faecalis* and *E. faecium*)14 (5.5) Other species3 (1.2)Gram-negative bacilli24 (9.4)Viridans streptococci group8 (3.1)Other^a^28 (11.0)^a^Includes Gram-positive cocci, *Staphylococcus* species coagulase not specified, *Streptococcus* *agalactiae* or group B streptococci, *Streptococcus dysgalactiae,* Gram-negative cocci, Gram-positive bacilli, fungi/yeast, viruses, and invalid/ambiguous pathogen code

Previous and Concomitant Antibiotic Therapy {#Sec9}
-------------------------------------------

Most patients (71.5%; *n* = 319) received other antibiotic therapy before daptomycin treatment; the most frequent antibiotics were penicillins (37.4%; *n* = 167), glycopeptides (32.5%; *n* = 145), and carbapenems (22.0%; *n* = 98) (Table [1](#Tab1){ref-type="table"}).

When daptomycin was administered with concomitant antibiotics (82.8%; *n* = 361), the most common antibiotics were carbapenems (51.2%; *n* = 185), penicillins (42.1%; *n* = 152), and aminoglycosides (19.9%; *n* = 72).

Daptomycin Prescribing Patterns {#Sec10}
-------------------------------

Daptomycin was used empirically (i.e., before culture results were known) in 56.1% (*n* = 250) of patients. Daptomycin was the first-line therapy for 27.5% (*n* = 121) of patients and second-line therapy for 72.5% (*n* = 319).

The most frequently prescribed doses of daptomycin were 6 mg/kg/day in 37.9% (*n* = 169) of patients and 4 mg/kg/day in 25.8% (*n* = 115) of patients. Although we cannot exclude that some patients received suboptimal daptomycin treatment, 4 mg/kg/day is the approved dose of daptomycin for cSSTI without bacteremia. A total of 16.0% (*n* = 71) of patients received doses \>6 and ≤10 mg/kg/day and 16.0% (*n* = 71) received doses \>4 to \<6 mg/kg/day; 3.4% (*n* = 15) of patients received \<4 mg/kg/day and 1.1% (*n* = 5) of patients had no record of dose.

The median duration of daptomycin therapy was 10.0 (range 1--58) days.

Clinical Outcomes {#Sec11}
-----------------

Clinical success (i.e., cured or improved) was reported for 77.1% (*n* = 344) of patients (46.2% were cured and 30.9% were improved). A total of 11.4% (*n* = 51) of patients were considered as clinical failures and 11.4% (*n* = 51) of patients were non-evaluable. Outcomes were comparable when analyzed by degree of neutropenia severity (Fig. [1](#Fig1){ref-type="fig"}). The success rate was 76.7% (*n* = 171) for patients with severe neutropenia (ANC ≤100 cells/mm^3^), 80.5% (*n* = 62) for moderate neutropenia (101--499 cells/mm^3^), and 78.6% (*n* = 103) for mild neutropenia (500--1000 cells/mm^3^). Clinical success was similar whether daptomycin was used as first-line or second-line therapy \[79.3% (*n* = 96) and 76.5% (*n* = 244), respectively\]. Success rate by primary infection type ranged from 73.1% (*n* = 19) for uncomplicated skin and soft tissue infections (uSSTI) to 93.3% (*n* = 14) for endocarditis (Fig. [2](#Fig2){ref-type="fig"}). The clinical success rates by infecting pathogen were high for CoNS (85.6%; *n* = 95) and *S.aureus* (77.1%; *n* = 39) (Fig. [3](#Fig3){ref-type="fig"}). The clinical success rates were similar regardless of daptomycin dose or dose range. Higher clinical success rates were observed with increased duration of daptomycin therapy (Fig. [4](#Fig4){ref-type="fig"}). The overall time to improvement was achieved within a median of 3 (range 1--30) days from initiation of daptomycin treatment.Fig. 1Clinical outcome by degree of neutropenia severity. Neutropenia severity was missing for *n* = 15 patientsFig. 2Clinical outcome by primary infection type. *cSSTI* complicated skin and soft tissue infection, *FBPI* foreign body/prosthetic infection, *uSSTI* uncomplicated skin and soft tissue infection. ^a^ Includes surgical/non-surgical antibiotic prophylaxis, urinary tract infection/pyelonephritis, necrotizing infections, metastatic abscess, septic arthritis, central nervous system infection, and otherwise unspecified infectionsFig. 3Clinical outcome by selected primary pathogens. *CoNS* coagulase-negative staphylococci, *MRSA* methicillin-resistant *Staphylococcus aureus*, enterococci included *Enterococcus faecalis*, *Enterococcus faecium* and other *Enterococcus* speciesFig. 4Overall clinical outcome by duration of daptomycin therapy

Safety {#Sec12}
------

AEs and SAEs, regardless of their relation to daptomycin, were reported in 19.3% (*n* = 86) and 15.2% (*n* = 68) of patients, respectively (Table [4](#Tab4){ref-type="table"}). Elevated serum creatine phosphokinase (CPK) was reported as an AE for one patient, but was considered to be unrelated to daptomycin by the investigator. CPK was measured at baseline for 216 patients and most (89.8%) had normal values (≤1 × upper limit of normal; ULN). Three (1.4%) patients had elevated CPK levels (\>10 × ULN) at baseline. An elevation in CPK was observed in two patients (from ≤10 × ULN at baseline to \>10 × ULN) during the study. There were no AEs of musculoskeletal and connective tissue disorders.Table 4Safety of daptomycin treatment in patients with neutropeniaSafety parameters*N* = 446*n* (%)Any AE86 (19.3) AEs possibly related to daptomycin7 (1.6) AEs leading to drug discontinuation27 (6.1)Any SAE68 (15.2) SAEs possibly related to daptomycin3 (0.7) SAEs leading to drug discontinuation24 (5.4)AEs occurring in \>1% patients Septic shock11 (2.5) Multiorgan failure9 (2.0) Neutropenia9 (2.0) Renal failure acute6 (1.3) Respiratory failure6 (1.3) Sepsis6 (1.3)*AE* adverse event, *SAE* serious AE

The total number of deaths was 50 (11.2%) during the study and were all unrelated to the study drug.

Discussion {#Sec13}
==========

Among the 446 patients with neutropenia from the EU-CORE registry who received daptomycin, there was a high clinical success rate (77.1%). The success rates did not differ according to neutropenia severity, as previously reported in the CORE study \[[@CR17]\].

Most study patients (56.1%) received daptomycin as empirical treatment. Indeed, the main objective of initial empirical antibiotic therapy in patients with neutropenia is to prevent serious morbidity and mortality resulting from bacterial infections \[[@CR5]\]. Empirical antibiotic regimen in febrile patients with neutropenia should be based on the risk status of the patient \[[@CR2]\]. However, despite decades of well-performed clinical trials, no single empirical therapeutic regimen for the initial treatment of febrile patients with neutropenia has emerged as being clearly superior to others \[[@CR5], [@CR21]\]. Thus, a recent Cochrane review concluded that the empirical routine addition of glycopeptides to anti-Gram-positive antibiotic treatment does not improve the outcomes of febrile patients with neutropenia and cancer \[[@CR22]\].

Both the increasing incidence and the array of antibiotic-resistant pathogens have become important challenges in the treatment of patients with neutropenia \[[@CR23], [@CR24]\]. Thus, both vancomycin and linezolid have limitations with respect to their use in patients with neutropenia. First, vancomycin is no longer a standard recommendation in initial antibiotic therapy for fever and neutropenia \[[@CR5]\]. In addition, a series of studies showed a relation between a higher vancomycin MIC of the infecting pathogen and a worse clinical outcome of patients with an MRSA infection \[[@CR10]\]. Second, although linezolid produced similar outcomes in febrile patients with neutropenia compared with vancomycin \[[@CR25]\], it is not bactericidal and might not be as effective as antibiotics such as daptomycin in eradicating catheter-related MRSA embedded in biofilm \[[@CR26]\]. Finally, SAEs associated with linezolid were reported after its commercial release, including cases of lactic acidosis, peripheral and optic neuropathy, and serotonin syndrome \[[@CR27]\].

Considering its once-daily administration, short infusion time, and good safety profile, daptomycin can be suggested as a therapeutic option of interest in patients with neutropenia, as reported in the Infectious Diseases Society of America (IDSA) guidelines \[[@CR5]\]. This favorable profile of daptomycin was confirmed in our analysis. Thus, the high clinical success rate reported at the end of daptomycin therapy was obtained with a median time to improvement of 3 days. Of interest, the clinical success rates were comparable for first-line (79.3%) or second-line (76.5%) treatments. There are only a few reports on the use of daptomycin in the treatment of patients with neutropenia and Gram-positives infections. Poutsiaka et al. reported a clinical success rate in four out of nine (44%) patients who had VRE bacteremia during episodes of fever and neutropenia \[[@CR16]\]. Rolston et al. reported an overall clinical success rate as high as 90% in 84 patients with cancer and neutropenia \[[@CR6]\]. There were some case reports on the use of daptomycin subsequent to vancomycin-induced neutropenia \[[@CR15]\] or the use of a combination of daptomycin and gentamicin in a neutropenic patient \[[@CR14]\]. The CORE study registry reported a high clinical success rate (85%) in 186 patients with neutropenia and documented Gram-positive infections \[[@CR17]\]. Daptomycin appears to be also suitable for outpatient therapy in cases of low-risk neutropenia \[[@CR6]\].

In addition to its high effectiveness, our analysis showed that daptomycin was well tolerated. Only seven (1.6%) patients experienced AEs possibly related to daptomycin and 27 (6.1%) patients discontinued daptomycin therapy because of AEs. Before the optimization of the dosing interval with a once-daily regimen, reversible elevated serum CPK, and skeletal muscle toxicity had been reported \[[@CR28]\]. In clinical trials with once-daily daptomycin, elevated CPK was reported in 7% of patients receiving 6 mg/kg/day, thus leading to study discontinuation in only 2.5% of patients. Elevated CPK was not reported in patients receiving 4 mg/kg/day \[[@CR29], [@CR30]\]. Our safety data show that the impact of daptomycin was minimal on the serum CPK level because only one patient had elevated CPK during treatment (unrelated to daptomycin, according to the investigator) and there were no AEs related to musculoskeletal disorders. There were no new or unexpected safety findings.

There are some limitations in our analysis that are inherent to non-comparative, non-blinded, and retrospective studies. A central laboratory was not used in this registry and, therefore, microbiologic results and susceptibility to antibiotics could be different across the different centers. Moreover, the clinical outcomes were subjectively assessed by the local investigators. Most patients received concomitant antibiotic treatments and, thus, the success of treatment related to daptomycin remains uncertain. Nevertheless, our data have been recorded in real-world conditions and the criteria of selection of patients were not stringent in contrast to randomized clinical trials. A large number of institutions could participate without restrictions. The only selection criteria for these daptomycin-treated patients were neutropenia at baseline or during daptomycin therapy, and not participating in interventional studies with daptomycin. These selection criteria and the absence of restriction on concomitant or prior antibiotic treatments enabled the inclusion of various infections. Thus, patients who urgently needed treatment because of their conditions were included in the registry, but would have been excluded in a controlled clinical trial. Although the population was almost unselected, the overall clinical success rate was high, thus suggesting that daptomycin was effective in a real-world population of patients with neutropenia.

Conclusion {#Sec14}
==========

Real-world data from the EU-CORE registry study suggest that daptomycin is effective and well tolerated in patients with neutropenia and Gram-positive infections. Results are consistent with those observed in previous studies in patients with neutropenia and cancer.
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